Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.

Engle DB, Belisle JA, Gubbels JA, Petrie SE, Hutson PR, Kushner DM, Patankar MS.

Gynecol Oncol. 2009 Mar;112(3):631-6.

PMID:
19263582
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.

Smith JA, Ngo H, Martin MC, Wolf JK.

Gynecol Oncol. 2005 Jul;98(1):141-5.

PMID:
15963813
[PubMed - indexed for MEDLINE]
3.

Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.

Stamelos VA, Robinson E, Redman CW, Richardson A.

Gynecol Oncol. 2013 Feb;128(2):377-82. doi: 10.1016/j.ygyno.2012.11.019. Epub 2012 Nov 17.

PMID:
23168176
[PubMed - indexed for MEDLINE]
4.

The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.

Cadron I, Van Gorp T, Mihalyi A, Luyten C, Drijkoningen K, Amant F, Leunen K, Vergote I.

Gynecol Oncol. 2010 Jul;118(1):64-8. doi: 10.1016/j.ygyno.2010.03.008. Epub 2010 May 1.

PMID:
20439112
[PubMed - indexed for MEDLINE]
5.

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, de Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F.

BMC Cancer. 2006 Jan 7;6:5.

PMID:
16398939
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

PMID:
23467907
[PubMed - indexed for MEDLINE]
7.

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA.

Gynecol Oncol. 2011 Apr;121(1):187-92. doi: 10.1016/j.ygyno.2010.11.017. Epub 2011 Jan 3.

PMID:
21208651
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.

Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C.

Anticancer Res. 2000 Sep-Oct;20(5C):4047-50.

PMID:
11268499
[PubMed - indexed for MEDLINE]
9.

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.

Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN.

Gynecol Oncol. 2006 Feb;100(2):389-96. Epub 2005 Nov 21.

PMID:
16300820
[PubMed - indexed for MEDLINE]
10.

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL.

Mol Cancer Ther. 2006 May;5(5):1197-208.

PMID:
16731752
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1997 May;15(5):1953-64.

PMID:
9164207
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.

Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, Slack-Davis JK.

Gynecol Oncol. 2014 Feb;132(2):455-61. doi: 10.1016/j.ygyno.2013.12.031. Epub 2013 Dec 28.

PMID:
24378876
[PubMed - indexed for MEDLINE]
14.

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-44-S15-52.

PMID:
9346222
[PubMed - indexed for MEDLINE]
15.

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group.

J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.

PMID:
15547181
[PubMed - indexed for MEDLINE]
Free Article
16.

Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Schlosshauer PW, Li W, Lin KT, Chan JL, Wang LH.

Gynecol Oncol. 2009 Sep;114(3):516-22. doi: 10.1016/j.ygyno.2009.06.002. Epub 2009 Jul 2.

PMID:
19576622
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.

Waltmire CN, Alberts DS, Dorr RT.

Anticancer Drugs. 2001 Aug;12(7):595-602.

PMID:
11487716
[PubMed - indexed for MEDLINE]
18.

Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor.

Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR.

Brain Res Dev Brain Res. 1991 Apr 24;59(2):221-30.

PMID:
1655307
[PubMed - indexed for MEDLINE]
19.

Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.

Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ.

Exp Neurol. 2008 Mar;210(1):229-37. Epub 2007 Nov 17.

PMID:
18078936
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

Taylor SA, Marrinan CH, Liu G, Nale L, Bishop WR, Kirschmeier P, Liu M, Long BJ.

Gynecol Oncol. 2008 Apr;109(1):97-106. doi: 10.1016/j.ygyno.2007.12.013. Epub 2008 Jan 31.

PMID:
18237771
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk